Store
Infectious Disease Diagnostic Testing: World Market Analysis, 2024-2029
Publication Date: November 19, 2024
Tags: In Vitro Diagnostics (IVD), Infectious Disease Testing Instruments, Infectious Diseases, Pharmaceuticals, Vaccines
Pages: 250
SKU: 24-024
As infectious diseases continue to pose significant global health challenges, diagnostic testing has emerged as a vital tool in detecting and managing these threats. Today, infectious disease testing stands at the forefront of the rapidly expanding in vitro diagnostics (IVD) industry, representing one of its largest and most dynamic segments.
This comprehensive market research report from Kalorama Information delves into the world of infectious disease IVD, presenting unparalleled insights and forecasts for 2024-2029. Designed for industry professionals, investors, and market strategists, this report will equip you with the knowledge needed to stay ahead in a competitive and rapidly evolving sector.
Stay Ahead of the Curve with Infectious Disease Diagnostic Testing: World Market Analysis, 2024-2029:
With the global demand for infectious disease IVD products projected to surge, understanding market trends is crucial for healthcare providers, investors, and industry stakeholders. This report offers a detailed analysis of the factors driving growth, including the increasing recognition of infectious diseases as a global health concern.
Report Features:
- Comprehensive Market Coverage: Understand the dynamic landscape of infectious disease diagnostics, spanning key test categories such as:
- Healthcare-Associated Infections (HAIs)
- COVID-19
- Hepatitis
- STIs
- Influenza
- HIV/AIDS
- Tuberculosis
- TORCH
- Other infectious diseases (including Dengue Fever, Emerging Infections, Fungal, Lyme Disease, Malaria, Other Parasitic, RSV, Streptococcal)
- Global Reach with Local Insights: Gain valuable perspectives on opportunities in diverse geographic regions, including North America, Western Europe, Asia/Pacific, and emerging markets across Central & South America, Africa, and the Middle East.
- Strategic Market Drivers: Explore the macroeconomic and healthcare trends driving the need for advanced diagnostics and how aging populations and globalized threats are influencing market growth.
- Competitive Intelligence: Analyze the leading players and their IVD innovations, helping you benchmark against industry leaders and identify potential partnerships or competitive advantages.
Scope and Methodology You Can Trust:
Backed by Kalorama Information’s extensive experience and robust analytical frameworks, this report synthesizes data from public records, epidemiological research, key competitor analysis, and economic modeling. Our insights are further enriched by expert interviews and proprietary databases, ensuring you get actionable, reliable forecasts.
Table of Contents
Chapter 1: Executive Summary
A Mix of Traditional and Emerging Testing Technologies
Market Drivers
The World Infectious Disease Testing Market
- Table 1-1: World Infectious Disease Diagnostic Test Market, 2024-2029 ($ million)
- Figure 1-1: World Infectious Disease Diagnostic Test Market, 2024-2029 ($ million)
Major Findings of the Report
- Table 1-2: Selected Infectious Diseases, Global Incidence, Prevalence, & Mortality, 2023 (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Sexually Transmitted Diseases [Chlamydia; Gonorrhea; Herpes HSV-2; Malaria; Syphilis; Trichomoniasis]; Tuberculosis; Typhoid Fever)
- Figure 1-2: Selected Infectious Diseases: Global Incidence of New Cases, 2023 (million) (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Sexually Transmitted Diseases; Tuberculosis; Typhoid Fever)
- Figure 1-3: Selected Sexually Transmitted Diseases: Global Incidence of New Cases and Chronic Cases, 2023 (million) (Sexually Transmitted Diseases [Chlamydia; Gonorrhea; Herpes HSV-2; HIV/AIDS; Malaria; Syphilis; Trichomoniasis])
- Figure 1-4: Selected Infectious Diseases: Global Deaths, 2023 (thousands) (COVID-19; Dengue Fever [symptomatic]; Hepatitis [all forms]; HIV/AIDS; HPV; Influenza [severe]; Sepsis; Tuberculosis; Typhoid Fever)
Scope and Methodology
Chapter 2: Market Environment
Overview
Population
- Table 2-1: Population by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
- Figure 2-1: Global Population, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
Age Distribution
- Table 2-2: Population 50 Years & Older by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
- Table 2-3: Population 65 Years & Older by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Macroeconomic Environment
Global Economic Outlook
- Table 2-4: Gross Domestic Product by Country, 2023-2029 ($ billion) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Per Capita Gross Domestic Product
- Table 2-5: Per Capita Gross Domestic Product by Country, 2023-2029 (dollars) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Global Healthcare Trends
Infectious Disease Cases
- Table 2-6: Number of Infectious Disease Cases by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
- Figure 2-2: Number of Global Infectious Disease Cases, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
Medical Providers
- Table 2-7: Medical Providers, Selected Countries, 2021 (Africa/M.E.; Canada; Central/South America; China; Eastern Europe; France; Germany; India; Italy; Japan; Mexico; Other Asia/Pacific; Other Western Europe; South Korea; Spain; United States)
Patient Activity
- Hospital Admissions
- Table 2-8: Hospital Admissions by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
- Inpatient Days
- Table 2-9: Inpatient Days by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
- Outpatient Consultations
- Table 2-10: Outpatient Consultations by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
- IVD Tests
- Table 2-11: IVD Tests by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
- Figure 2-3: In Vitro Diagnostic (IVD) Tests, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
Chapter 3: Infectious Disease IVD Products & Markets
Overview
- Table 3-1: Global Infectious Disease IVD Products Demand by Type, 2024-2029 ($ million) (COVID-19; Healthcare-Associated Infections [HAIs]; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
- Figure 3-1: Global Infectious Disease IVD Products Demand by Disease/Area, 2024-2029 ($ million) (COVID-19; Healthcare-Associated Infections [HAIs]; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Healthcare-Associated Infections (HAIs)
- Table 3-2: Global Healthcare-Associated Infection (HAIs) IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: C. diff, MRSA, Sepsis, VRE, Other HAIs; Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
Clostridium difficile (C. diff)
Sepsis
Methicillin-Resistant Staphylococcus Aureus (MRSA)
Vancomycin-Resistant Enterococcus (VRE)
Other HAIs
COVID-19
- Table 3-3: Global COVID-19 IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular Tests)
Hepatitis IVD Products
- Table 3-4: Global Hepatitis IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: Hepatitis B, Hepatitis C, Other; Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular)
Sexually Transmitted Infections (STIs)
- Table 3-5: Global Sexually Transmitted Infection (STI) IVD Products Demand, 2024-2029 ($ million) (Pathogen/Disorder: Chlamydia, Gonorrhea, HPV, HSV-2 [Herpes Simplex], Syphilis, Other STIs; Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
Human Papillomavirus (HPV)
Chlamydia Trachomatis (Chlamydia)
Gonorrhea
Herpes Simplex Virus 2 (HSV-2)
Syphilis
Other Sexually Transmitted Disease (STD) IVD Products
Influenza
- Table 3-6: Global Influenza IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
HIV/AIDS IVD Products
- Table 3-7: Global HIV/AIDS IVD Products Demand, 2024-2029 ($ million) (Site: Blood Screens, Laboratory Tests, POC Tests; Technology: Immunoassay, Molecular)
Tuberculosis (TB)
- Table 3-8: Global Tuberculosis IVD Products Demand, 2024-2029 ($ million) (Site: Laboratory Tests, POC Tests; Technology: Immunoassay, Microbiology, Molecular)
TORCH
- Table 3-9: Global TORCH IVD Products Demand, 2024-2029 ($ million)
All Other Infectious Disease IVD Products
- Table 3-10: Global Other Infectious Disease IVD Products Demand, 2024-2029 ($ million) (Dengue Fever; Emerging Infections; Fungal; Lyme Disease; Malaria; Other Parasitic; RSV; Streptococcal; All Other)
Malaria
Emerging Infections
Chikungunya
Fungal Infections
Other Parasitic Conditions
Lyme Disease
Respiratory Syncytial Virus (RSV)
Streptococcal Infections
Dengue Fever
All Other Products
Global Infectious Disease IVD Technologies
- Table 3-11: Global Infectious Disease IVD Products Demand by Technology, 2024-2029 ($ million) (Immunoassay, Microbiology, Molecular)
Immunoassays
- Table 3-12: Global Immunoassay Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other)
Molecular Technologies
- Table 3-13: Global Molecular Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; Tuberculosis; Other)
Microbiological Testing
- Table 3-14: Global Microbiology Infectious Disease IVD Products Demand, 2024-2029 ($ million) (HAIs/Sepsis; Influenza; STIs; Tuberculosis; Other)
Pathogen ID/AST Techniques
- Table 3-15: Global Microbiology ID/AST IVD Products Demand, 2024-2029 ($ million) (Blood Culture; Chromogenic Media; ID/AST Auto; ID/AST Panels; Mass Spectrometry; Rapid Microbiology)
Automated ID/AST Products
Manual Panels & Reagents
Producers
Global Infectious Disease IVD Demand by Market
- Table 3-16: Global Infectious Disease IVD Products Demand by Site, 2024-2029 ($ million) (Blood Screens; Laboratory; Point-of-Care)
- Table 3-17: Global Laboratory Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
- Table 3-18: Global Point-of-Care Infectious Disease IVD Products Demand, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; Tuberculosis; Other Infections)
Chapter 4: Global Markets
Overview
- Table 4-1: Infectious Disease IVD Products Demand, by Country, 2024-2029 ($ million) (Asia/Pacific [China, India, Japan, South Korea, Other APAC]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other Western Europe]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
North America
- Table 4-2: North America: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
United States
- Table 4-3: United States: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Canada
- Table 4-4: Canada: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Mexico
- Table 4-5: Mexico: Infectious Disease IVD Products Demand by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Western Europe
- Table 4-6: Western Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Germany
- Table 4-7: Germany: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
France
- Table 4-8: France: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
United Kingdom
- Table 4-9: United Kingdom: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Italy
- Table 4-10: Italy: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Spain
- Table 4-11: Spain: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Other Western Europe
- Table 4-12: Other Western Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
- Switzerland
- Netherlands
- Sweden
- Belgium
- Austria
- Denmark
- Norway
- Portugal
- Ireland
- Greece
- Finland
- All Other Countries & Territories
Asia/Pacific
- Table 4-13: Asia/Pacific: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
China
- Table 4-14: China: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Japan
- Table 4-15: Japan: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
India
- Table 4-16: India: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
South Korea
- Table 4-17: South Korea: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Other Asia/Pacific
- Table 4-18: Other Asia/Pacific: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Malaysia
- Pakistan
- Vietnam
- All Other Countries & Territories
Other Regions
- Table 4-19: Other Regions: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
Africa/Middle East
- Table 4-20: Africa/Middle East: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
- Turkey
- Saudi Arabia
- Iran
- Egypt
- Iraq
- Nigeria
- South Africa
- Israel
- United Arab Emirates
- All Other Countries & Territories
Central & South America
- Table 4-21: Central & South America: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
- Brazil
- Argentina
- Colombia
- Peru
- Chile
- All Other Countries & Territories
Eastern Europe
- Table 4-22: Eastern Europe: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
- Russia
- Poland
- Romania
- Czech Republic
- Hungary
- All Other Eastern Europe Countries
Chapter 5: Company Profiles
Abbott Laboratories
Infectious Diseases – Molecular
COVID-19
HIV Point of Care
Blood Bank
Becton Dickinson and Company
Molecular Microbiology
Traditional Microbiology – ID/AST
Blood Culture
Hospital Acquired Infections
Molecular Microbiology
Traditional Microbiology – ID/AST
Blood Culture
Mass Spectrometry
Bio-Rad Laboratories
Immunoassays
bioMérieux
Traditional Microbiology
Blood Culture
Immunoassays
BIOFIRE Diagnostics Business
Mass Spectrometry
Bruker Corporation
Danaher Corporation
Tuberculosis
Microbiology
POC Testing Developments
DiaSorin
Recent Deals and Announcements
Grifols S.A.
Blood Transfusion Business
Hologic
PANTHER Molecular System
HIV Testing
Sexually Transmitted Infections
Infectious Diseases
QIAGEN
Tuberculosis
Molecular Expansion
QuidelOrtho Corporation
Solana Business
Molecular – Savanna
COVID-19
Roche Holding
Immunoassays
COVID-19
Blood Screening
HPV
Other Recent Developments
Siemens Healthineers
Thermo Fisher Scientific
Microbiology
Molecular Test Business
COVID-19
Related products
IVD Market Trends Report, March 2023
March 17, 2023
Diagnostic testing remains a cornerstone in healthcare, aiding physicians in diagnosis and providing crucial information for treatments like precision medicine. As we navigate the aftermath of the COVID-19 pandemic, the IVD market is evolving, driven by new products, shifts in global health spending, regulatory updates, and changing disease trends. Despite these shifts, the IVD market…
Price range: $3,000.00 through $4,500.00
Hematology and Coagulation Markets, 2023
April 5, 2023
Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.
Key Insights Provided:
- Market sizing…
Price range: $3,000.00 through $4,500.00
Cell and Gene Therapy Market and Deals Analysis, 2023
May 22, 2023
Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals tracks deal-making and market opportunities in cell and gene therapy, providing specific details of 1000+ deals from 2022-2023. With a staggering $40 billion in CGT deals in 2022 alone, understanding the market dynamics and key…
Price range: $4,000.00 through $6,000.00
![30-Country In Vitro Diagnostic (IVD) Market Atlas [October 2023 Update]](https://www.scienceandmedicinegroup.com/wp-content/uploads/2025/06/Kalorama-1.svg)